Overview

A Study to Determine the Activity of Caelyx With Trastuzumab and Docetaxel in the Treatment of Metastatic Breast Cancer (Study P03679)

Status:
Completed

Trial end date:
2008-10-24

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate, in a first stage, the safety (incidence of cardiac toxicity) of Caelyx in combination with Trastuzumab and Docetaxel; and in a second stage, the tumor response rate of this regimen. This study will be conducted in approximately 30 centers. A total of approximately 70 to 95 subjects will be enrolled.

Phase:

Phase 2

Details

Lead Sponsor:

Merck Sharp & Dohme Corp.

Collaborator:

MDS Pharma Services

Treatments:

Docetaxel
Doxorubicin
Liposomal doxorubicin
Trastuzumab